Monitor prolactin levels in transgender females on estrogen
STEP 1 — Gather Information
Collect baseline prolactin, estradiol, and testosterone levels; assess for symptoms of hyperprolactinemia (galactorrhea, headache, visual changes); review current estrogen dose and type, and concomitant medications (e.g., spironolactone, antipsychotics) that may affect prolactin.
STEP 2 — Rule In / Rule Out
If prolactin exceeds the upper limit of normal (lab-specific, e.g., >20 ng/mL), proceed to evaluate for prolactinoma; otherwise, continue routine monitoring per schedule.
STEP 3 — Classify or Stratify
If prolactin is elevated, assess symptom severity and consider pituitary imaging; if prolactin remains within normal limits, maintain scheduled monitoring.
STEP 4 — Decide
If MRI reveals a pituitary lesion, refer to endocrinology or neurosurgery and consider dose reduction of estrogen or adding cabergoline; if no lesion and prolactin is mildly elevated (<2× ULN), repeat prolactin in 3 months; if normal, repeat prolactin annually for the first year then every 2 years thereafter.
Clinical Guardrails / Mimics / Pitfalls
Do not discontinue estrogen solely for asymptomatic mild prolactin elevation without evaluation; do not mistake macroprolactin for true hyperprolactinemia (consider polyethylene glycol precipitation test if discrepancy); do not overlook medication‑induced prolactin rise (e.g., antipsychotics, anti‑emetics); do not delay imaging in symptomatic patients with markedly elevated prolactin (>5× ULN) or visual field defects.
Concrete Clinical Example
A 22‑year‑old transgender female on estradiol 4 mg daily and spironolactone 100 mg daily presents for routine follow‑up. Baseline prolactin was 12 ng/mL. At 12‑month visit, prolactin is 38 ng/mL (ULN 20 ng/mL). She denies galactorrhea or headaches; estradiol is 150 pg/mL, testosterone <50 ng/dL. Prolactin is moderately elevated without symptoms, so repeat prolactin in 3 months; if persistent, order pituitary MRI.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Wylie C. Hembree et al., Endocrine Society, 2017, doi:10.1210/jc.2017-01658